.png){kind=logo}
Stock image for illustration purposes only - book cover, edition or condition may vary.
Interferon Alpha-2: Pre-clinical and Clinical Evaluation
. Ed(S): Kisner, Daniel L.; Smyth, J. F.
€ 126.10
FREE Delivery in Ireland
Description for Interferon Alpha-2: Pre-clinical and Clinical Evaluation
Paperback. Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984 Editor(s): Kisner, Daniel L.; Smyth, J. F. Series: Developments in Oncology. Num Pages: 112 pages, black & white illustrations, bibliography. BIC Classification: MJCL. Category: (G) General (US: Trade). Dimension: 235 x 155 x 7. Weight in Grams: 207.
Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus cular and subcutaneous routes. Clinical toxicity principally involves the 'influen za like' syndrome previously seen with native interferons. Other important toxi cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non Hodgkin's lymphomas (both low ... Read more
Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus cular and subcutaneous routes. Clinical toxicity principally involves the 'influen za like' syndrome previously seen with native interferons. Other important toxi cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non Hodgkin's lymphomas (both low ... Read more
Product Details
Format
Paperback
Publication date
2011
Publisher
Springer-Verlag New York Inc. United States
Number of pages
112
Condition
New
Series
Developments in Oncology
Number of Pages
112
Place of Publication
New York, NY, United States
ISBN
9781461296188
SKU
V9781461296188
Shipping Time
Usually ships in 15 to 20 working days
Ref
99-15
Reviews for Interferon Alpha-2: Pre-clinical and Clinical Evaluation